Blood concentration and urinary excretion of captopril (SQ 14,255) , angiotensin converting enzyme activity and R-A-A system after administration of captopril--in patients with chronic renal failure compared with essential hypertension
Miyazaki, N.; Shionoiri, H.; Uneda, S.; Yasuda, G.; Gotoh, E.; Fujishima, S.; Kaneko, Y.; Kawahara, Y.; Yamazaki, Y.
Nihon Jinzo Gakkai Shi 24(4): 421-428
1982
ISSN/ISBN: 0385-2385 PMID: 6750186 Document Number: 188690
Document emailed within 1 workday
Related Documents
Almazov, V.A.; Ametov, A.S.; Shliakhto, E.V.; Dolgova, I.B.; Pushkarev, A.A. 1989: Neurohumoral mechanisms regulating renal blood circulation in patients with hypertension undergoing captopril block of angiotensin-converting enzyme Terapevticheskii Arkhiv 61(8): 13-15Ryan, E.; Muldowney, F.P. 1983: Use of angiotensin i to Ii converting enzyme inhibitor S.Q. 14225 (captopril), in moderate essential hypertension Irish Medical Journal 76(4): 175; 177-178
Larochelle, P.; Genest, J.; Kuchel, O.; Boucher, R.; Gutkowska, Y.; McKinstry, D. 1979: Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity Canadian Medical Association Journal 121(3): 309-316
Kondo, K.; Kida, O.; Kodama, K.; Higa, T.; Someya, N.; Morotomi, Y.; Tanaka, K. 1985: Comparison of the acute effects of three structurally different converting enzyme inhibitors (captopril, SA-446 and MK-421) on blood pressure, the renin-angiotensin system and the kallikrein-kinin system Nihon Jinzo Gakkai Shi 27(3): 337-342
Singh, R.; Kalra, O.P.; Sarma, P.U.; Prabhu, K.M. 1996: Effect of captopril on serum angiotensin converting enzyme and blood pressure in hypertensive patients Journal of the Association of Physicians of India 44(2): 109-111
Tajima, J.; Abe, K.; Yasujima, M.; Tanno, M.; Yoshinaga, K. 1984: Effects of 3 different angiotensin converting enzyme inhibitors, MK 421, SQ 14225 and SA 446 on renal function and blood pressure in patients with essential hypertension Nihon Jinzo Gakkai Shi 26(6): 779-789
Kida, O.; Kodama, K.; Higa, T.; Someya, N.; Kondo, K.; Morotomi, Y.; Tanaka, K. 1984: Effects of captopril on renin-angiotensin-aldosterone system and kallikrein-kinin system in patients with essential hypertension Nihon Jinzo Gakkai Shi 26(11): 1487-1493
Lijnen, P.; Staessen, J.; Amery, A. 1982: Assay of plasma angiotensin-converting enzyme activity in captopril-treated subjects Methods and Findings in Experimental and Clinical Pharmacology 4(6): 413-415
Xin, Z.-h.; Ma, H.-l.; Wu, S.-y.; Dai, C.-h. 2003: Determination of the inhibitory activity of angiotensin-converting enzyme inhibitor captopril by high performance capillary electrophoresis Yao Xue Xue Bao 38(11): 843-845
Mueller, S.M.; Cohen, M.L. 1985: Evidence for a captopril-sensitive angiotensin converting enzyme in the hindquarter vasculature of SHR and WKY Artery 12(6): 337-345
Fagard, R.; Amery, A.; Lijnen, P.; Staessen, J. 1980: First dose effect of the oral angiotensin converting enzyme inhibitor captopril Archives Internationales de Pharmacodynamie et de Therapie Suppl: 178-187
Antelava, N.A.; Gongadze, N.V.; Gogolauri, M.I.; Kezeli, T.D.; Pachkoriia, K.Z. 2007: Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin Ii receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits Georgian Medical News 150: 57-60
Rasmussen, S.; Ibsen, H.; Giese, J. 1984: Contrasting effects of the renin-angiotensin system on renal function disclosed during converting enzyme inhibition in patients with renal hypertension Scandinavian Journal of Urology and Nephrology. Supplementum 79: 49-52
Atlas, S.A.; Case, D.B.; Yu, Z.Y.; Laragh, J.H. 1984: Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril American Journal of Medicine 77(2a): 13-17
Cohen, M.L.; Kurz, K.D. 1982: Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421 Journal of Pharmacology and Experimental Therapeutics 220(1): 63-69
Oda, M.; Ino, Y.; Suzuki, K.; Sato, T.; Iwamoto, S.; Iwaki, M. 1989: Angiotensin converting enzyme inhibitory activity of MK-0521 in vivo and antihypertensive effect of its single oral administration on blood pressure and effect on the renin-angiotensin system in 2-kidney Goldblatt hypertensive dogs Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 93(4): 225-234
Brunner, H.R.; Waeber, B.; Wauters, J.P.; Turin, G.; McKinstry, D.; Gavras, H. 1978: Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure Lancet 2(8092 Pt 1): 704-707
Ramirez, A.J.; Migliorini, M.; Gilbert, B.H.; Marco, E.J.; Sanchez, R.A. 1991: Non-modulating essential hypertension: renal hemodynamic effects of long-term angiotensin converting enzyme inhibition Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 9(6): S396-S397
Soares, G.P.; Romaldini, H.; dos Santos, M.L.; Ratto, O.R. 1989: The role of angiotensin-converting enzyme inhibitor (captopril) on the mechanism of hypoxic pulmonary vasoconstriction. Experimental study in dogs Arquivos Brasileiros de Cardiologia 52(6): 307-314
Sakai, K.; Shiraki, Y.; Akima, M.; Imagawa, J.; Hinohara, Y.; Koga, T.; Ichihara, T.; Tohira, Y. 1988: Tissue angiotensin-converting enzyme blockade by MC-838 (altiopril calcium) infused intravenously to miniature pigs: comparison with captopril Archives Internationales de Pharmacodynamie et de Therapie 294: 228-240